Introduction: Sclerostin is a glycoprotein secreted by osteocytes and has anti-anabolic properties. High sclerostin levels in cases with chronic renal disease are associated with an increased risk of mineral and bone metabolism disorders.
Objectives: The aim of this study was to determine the correlation between serum sclerostin levels and nutritional factors, anemia severity and dialysis adequacy in end-stage renal disease (ESRD) on maintenance hemodialysis.
Patients and Methods: This descriptive-analytic study was conducted on 89 diabetic and non-diabetic hemodialysis individuals. The data including age, gender, body mass index (BMI), duration of the disease was extracted from patients’ records. The dialysis adequacy was determined using the urea reduction ratio (URR) and Kt/V indices. Blood samples were collected to determine the levels of calcium, phosphorus, albumin, intact parathyroid hormone and sclerostin.
Results: According to the results, mean parathyroid hormone and duration of chronic renal failure were higher in the non-diabetics than those in the diabetic population (P<0.05). In non-diabetic patients, serum sclerostin had a negative correlation with plasma hemoglobin, calcium, serum phosphate and BMI. Serum sclerostin also had a positive correlation with URR and Kt/V. In diabetic patients, sclerostin had a negative correlation with plasma hemoglobin and parathyroid hormone, which was significant with hemoglobin (r=-0.343, P=0.021). Furthermore, in diabetic patients, sclerostin had a positive relationship with BMI, URR and Kt/V, which was significant with URR (r=0.463, P=0.001).
Conclusion: The results showed the correlation of sclerostin with various biochemical and nutritional factors, however our results requites further investigation by larger studies.